Corcept Therapeutics Incorporated (CORT) Sees Large Increase in Short Interest

Lloyd Doyle
January 13, 2018

The biotechnology company reported $0.11 EPS for the quarter, missing analysts' consensus estimates of $0.13 by ($0.02). The Market Cap of the company is $2.29 Billion. The Average Volume of the company is 1.8 Million, while the Volume of the company in the last trading session was 2.98 Billion. The shares now trade at $19.94 and have been able to report a change of 9.92% over the past one week. According to the latest data, the consensus recommendation for Corcept Therapeutics Incorporated (CORT) is Outperform. Renaissance Technologies LLC now owns 2,683,400 shares of the biotechnology company's stock worth $31,664,000 after purchasing an additional 824,900 shares during the last quarter.

Short interest or otherwise called the percentage of a stock's tradable shares now being shorted is another data that investors use to get a handle on sentiment. The stock increased 0.08% or $0.04 during the last trading session, reaching $50.51. About 43,498 shares traded. Integra LifeSciences Holdings Corporation (NASDAQ:IART) has risen 32.67% since January 12, 2017 and is uptrending. It has outperformed by 241.69% the S&P500.

Since January 1, 0001, it had 0 insider buys, and 2 insider sales for $283,125 activity. A 3 analysts rate it as either a buy or a strong buy, while1 believe that investors should either steer clear of CORT or, if they already own its stock, sell it. Therefore 100% are positive. There are brokerage firms with lower targets than the average, including one setting a price target of $6.

A number of research analysts recently issued reports on CORT shares. As per Thursday, August 24, the company rating was maintained by Piper Jaffray. The firm has "Buy" rating given on Thursday, February 2 by Ladenburg Thalmann. Finally, Piper Jaffray Companies set a $12.00 price target on Corcept Therapeutics and gave the company a "buy" rating in a research report on Wednesday, October 19th. The company was maintained on Friday, September 8 by Piper Jaffray.


Investors sentiment decreased to 1.96 in 2017 Q3. It dived, as 13 investors sold Corcept Therapeutics Incorporated shares while 39 reduced holdings. 47 funds opened positions while 55 raised stakes. Bridgeway Cap Mgmt Incorporated owns 37,800 shares. Peak6 Investments Lp accumulated 0.03% or 110,485 shares.

Corcept Therapeutics Incorporated (NASDAQ:CORT) closed up +0.04 points or 0.19% at $20.85 with 1.86 mln shares exchanging hands. First Pacific Advsr Ltd Liability Company has invested 4.06% in CIT Group Inc. Robeco Institutional Asset Bv has 0% invested in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 17,624 shares. 134.52 million shares or 7.51% less from 145.43 million shares in 2017Q2 were reported. Acadian Asset Mngmt Limited Liability Corp invested in 2.30 million shares. United Services Automobile Association invested 0% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Jpmorgan Chase & Company has 0% invested in Corcept Therapeutics Incorporated (NASDAQ:CORT). Ameritas Ptnrs reported 0.01% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Susquehanna Gp Llp holds 0% or 67,778 shares. The Illinois-based Northern Tru has invested 0.01% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Vanguard Group Inc. grew its holdings in shares of Corcept Therapeutics by 18.4% during the second quarter. The number of shares that were traded during the day was 1.86 million, which corresponds to its 3-month volume average of 1.74 million shares a day.

Corcept Therapeutics Incorporated earnings have risen with an annualized rate of 16.9% over the last 5 years. Geode Management Ltd Llc has 0.01% invested in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 962,957 shares. CORT's profit will be $21.68 million for 27.13 P/E if the $0.19 EPS becomes a reality. The 1-year high was reported on Jan, 12 by Barchart.com. Also, Director G Leonard Baker, Jr. sold 30,000 shares of the company's stock in a transaction on Monday, November 13th. To see the other side of picture, profit margin of CORT stands at positive 27.30%; that indicates a firm actually every dollar of sales keeps in earnings. Rhumbline Advisers boosted its holdings in shares of Corcept Therapeutics by 21.5% in the second quarter. 70,034 were reported by 1492 Capital Management Ltd Liability.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER